Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-Oxycodone Antibody (A12)

Catalog #:   RGK12901 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG2a
Applications: ELISA
Accession: CAS: 76-42-6
Overview

Catalog No.

RGK12901

Species reactivity

General

Host species

Mouse

Isotype

IgG2a

Clonality

Monoclonal

Target

Oxycodone, Dihydrone, Dihydrohydroxycodeinone, Oxycodeinone, Dihydroxycodeinone

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

CAS: 76-42-6

Applications

ELISA

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

A12

Data Image
References

Bivalent Hapten Display Strategies for Conjugate Vaccines Targeting Opioid Mixtures Containing Fentanyl., PMID:40091228

Simultaneous measurement of fentanyl, fentanyl analogues and other drugs of abuse by multiplex bead assay., PMID:39882798

The development of opioid vaccines as a novel strategy for the treatment of opioid use disorder and overdose prevention., PMID:39831679

The immunological and pharmacokinetic evaluation of Lipid-PLGA hybrid nanoparticle-based oxycodone vaccines., PMID:39182328

Opioid-Based Haptens: Development of Immunotherapy., PMID:39063024

From Wheelchair Bound to Working: A Case Study of Intravenous Ketamine Infusions in Treating Stiff Person Syndrome., PMID:38817534

Multivalent Vaccination Strategies Protect against Exposure to Polydrug Opioid and Stimulant Mixtures in Mice and Rats., PMID:38357285

Blocking IL-17A prevents oxycodone-induced depression-like effects and elevation of IL-6 levels in the ventral tegmental area and reduces oxycodone-derived physical dependence in rats., PMID:38199516

A bacteriophage virus-like particle vaccine against oxycodone elicits high-titer and long-lasting antibodies that sequester drug in the blood., PMID:38160131

Investigation of monoclonal antibody CSX-1004 for fentanyl overdose., PMID:38052779

Immunotherapeutic strategies for treating opioid use disorder and overdose., PMID:36696567

Structures of drug-specific monoclonal antibodies bound to opioids and nicotine reveal a common mode of binding., PMID:36513069

An Immunconjugate Vaccine Alters Distribution and Reduces the Antinociceptive, Behavioral and Physiological Effects of Fentanyl in Male and Female Rats., PMID:36365109

Does anti-nerve growth factor monoclonal antibody treatment have the potential to replace nonsteroidal anti-inflammatory drugs and opioids in treating hip or knee osteoarthritis? A systematic review of randomized controlled trials., PMID:35900204

Pre-clinical safety and toxicology profile of a candidate vaccine to treat oxycodone use disorder., PMID:35469698

Housing conditions and microbial environment do not affect the efficacy of vaccines for treatment of opioid use disorders in mice and rats., PMID:34411500

Contribution of Antibody-Mediated Effector Functions to the Mechanism of Efficacy of Vaccines for Opioid Use Disorders., PMID:34281999

Pharmacological mechanisms underlying the efficacy of antibodies generated by a vaccine to treat oxycodone use disorder., PMID:34126123

[Role of Palliative Care in the Introduction of Chemotherapy in Patients with Poor Performance Status]., PMID:34006726

An assessment of the effectiveness of regional analgesia after VATS measured by an objective method for assessing testosterone, cortisol, α-amylase, sIgA, and β-endorphin levels - a randomised controlled trial., PMID:33619708

Mechanisms of interleukin 4 mediated increase in efficacy of vaccines against opioid use disorders., PMID:33101712

Anti-Opioid Antibodies in Individuals Using Chronic Opioid Therapy for Lower Back Pain., PMID:33073189

Monoclonal Antibodies Counteract Opioid-Induced Behavioral and Toxic Effects in Mice and Rats., PMID:32980813

Combining a Candidate Vaccine for Opioid Use Disorders with Extended-Release Naltrexone Increases Protection against Oxycodone-Induced Behavioral Effects and Toxicity., PMID:32586850

Polymer-mediated delivery of vaccines to treat opioid use disorders and to reduce opioid-induced toxicity., PMID:32439214

Vaccine blunts fentanyl potency in male rhesus monkeys., PMID:31369740

Development of vaccines to treat opioid use disorders and reduce incidence of overdose., PMID:31173759

Dexmedetomidine enhances glymphatic brain delivery of intrathecally administered drugs., PMID:31067483

Formulation and Characterization of Conjugate Vaccines to Reduce Opioid Use Disorders Suitable for Pharmaceutical Manufacturing and Clinical Evaluation., PMID:31018096

Alum adjuvant is more effective than MF59 at prompting early germinal center formation in response to peptide-protein conjugates and enhancing efficacy of a vaccine against opioid use disorders., PMID:30625019

Paraneoplastic Encephalopathy in a Patient With Metastatic Lung Cancer: A Case Study., PMID:30588355

Serological biomarker profiles of rapidly progressive osteoarthritis in tanezumab-treated patients., PMID:30576794

Dilution of Urine Followed by Adulteration in an Attempt to Deceive the Laboratory., PMID:30192938

Prophylactic vaccination protects against the development of oxycodone self-administration., PMID:29936242

Blocking interleukin-4 enhances efficacy of vaccines for treatment of opioid abuse and prevention of opioid overdose., PMID:29615715

A Stable Heroin Analogue That Can Serve as a Vaccine Hapten to Induce Antibodies That Block the Effects of Heroin and Its Metabolites in Rodents and That Cross-React Immunologically with Related Drugs of Abuse., PMID:29236495

Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse., PMID:29194445

Thrombotic microangiopathy associated with intravenous injection of extended-release oxycodone., PMID:28716778

Clinical pearls in pulmonary diseases., PMID:28651690

Desomorphine Screening Using Commercial Enzyme-Linked Immunosorbent Assays., PMID:28369523

An Advance in Prescription Opioid Vaccines: Overdose Mortality Reduction and Extraordinary Alteration of Drug Half-Life., PMID:28103678

Corrections., PMID:27646808

Efficacy and safety of fulranumab as monotherapy in patients with moderate to severe, chronic knee pain of primary osteoarthritis: a randomised, placebo- and active-controlled trial., PMID:27238963

[A Case of Multiple Bevacizumab-Related Colonic Perforations during Opioid Use]., PMID:26809533

[A Case of Advanced Breast Cancer in Which Marked Improvement of Joint Pain Was Obtained with Stepwise Dose Reduction of Trastuzumab Emtansine (T-DM1)]., PMID:26805183

Effect of estrogen on morphine- and oxycodone-induced antinociception in a female femur bone cancer pain model., PMID:26802873

A simple nonradioactive method for the determination of the binding affinities of antibodies induced by hapten bioconjugates for drugs of abuse., PMID:26677020

The frequency of naive and early-activated hapten-specific B cell subsets dictates the efficacy of a therapeutic vaccine against prescription opioid abuse., PMID:25972483

[A case of stage IV breast cancer with improved cancer pain using bevacizumab and paclitaxel]., PMID:25812505

Key findings from a national enhanced HIV surveillance system: 2010 - 2012., PMID:29769871

Datasheet
$ 328
Product specifications
100 μg 328 1 mg 1640

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Oxycodone Antibody (A12) [RGK12901]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only